Alongside the renal failure and fluid retention signals confirmed for the five studied BCR-ABL TKIs, a nephrotic syndrome signal was identified for dasatinib and nilotinib, a renal artery stenosis signal for nilotinib and ponatinib, and a thrombotic microangiopathy signal for dasatinib. This evidence concerns the gene ABL1 and kidney failure.